Industry News

Boston Scientific Corporation announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his new position, Professor Meredith will lead clinical and medical affairs across Boston Scientific and will provide global leadership of the company's clinical trial strategy. Professor Meredith will succeed Executive Vice President and Global..."/>
Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
Genomic Health, Inc. today announced results from eight Oncotype DX ® Breast Recurrence Score™ presentations at the European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark, highlighting superior clinical evidence in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. Specifically, prospective clinical outcomes in more than 7,400..."/>
Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients
Endocyte, Inc., a leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy, presented poster updates on its two lead clinical programs at the European Society for Medical Oncology 2016 Congress, being held in Copenhagen, Denmark October 7-11, 2016.. “We are pleased that both EC1456 and EC1169 have shown anti-tumor activity during the dose escalation phase of their respective trials,..."/>
Endocyte Presents Data on Two Lead Clinical Programs at European Society for Medical Oncology (ESMO) 2016 Congress
Spark Therapeutics, a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments, announced today that members of company management and a principal investigator will participate in the following American Association of Ophthalmology Annual Meeting events between Oct. 13 and Oct. 18:. 2016 Ophthalmology Innovation Summit, or..."/>
 Spark Therapeutics to Participate in AAO Annual Meeting
Alliqua BioMedical, Inc., a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that the Company’ s MIST Therapy System ® is now eligible for coverage in the geographic regions covered by First Coast Service Options Inc., a Medicare Administrative Contractor, or“ MAC.” The MIST Therapy System uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the..."/>
Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement Coverage for MIST Therapy®
Centene earns NCQA’s commendable accreditation status
AxoGen prices public offering at USD7.50 per share
SIGA Technologies, Inc. today announced that the Record Date for the Company’ s previously announced proposed rights offering is October 12 th, 2016.. We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is Tecovirimat, TPOXX ®, also known as ST-246 ®, an orally administered antiviral drug that targets orthopoxvirus infections."/>
SIGA Announces Oct. 12 Record Date for Rights Offering
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Data Monitoring Committee for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy met on October 7, 2016 and recommended continuation of the trial without modification. The APOLLO DMC met at the request of the Company following the decision–..."/>
Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
Compugen Ltd., a leading predictive drug discovery company, today announced that the Company will issue its quarterly financial statements for the third quarter 2016 on Monday, November 7. The Company also announced today that it will host its third quarter conference call the following week, on Wednesday, November 16, 2016 at 10:00 am ET."/>
Compugen Third Quarter Financial Statements to be Released November 7, 2016
AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will host a live webcast briefing regarding data as of September 15, 2016,..."/>
AveXis to Host Webcast Update of Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from two clinical trials, including the TANZANITE trial,“ Safety and..."/>
Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
Great Basin Scientific, Inc., a molecular diagnostics company, announced today that its common stock will begin trading on the OTC Market Group’ s OTCQB marketplace effective at the open of the market on October 11, 2016. The trading symbol will remain GBSN.. As previously announced, a Nasdaq Hearings Panel had granted the Company an extension of time to demonstrate compliance with the $35 million market value of listed securities requirement for..."/>
Great Basin Scientific Announces Transfer to the OTCQB Marketplace

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology1,026 Articles
Consumer Discretionary815 Articles
Financials749 Articles
Health Care639 Articles
Industrials579 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at